P
Passkey Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2023
Discovering new medicines by unlocking rational polypharmacology MoreLess
Metabolic Passkey Therapeutics is dedicated to the discovery of new medicines targeting complex diseases with multifactorial causes. The company operates in the pharmaceutical sector, focusing on metabolic diseases such as lipid disorders, obesity, and diabetes, as well as various forms of cancer. Utilizing a Rational Polypharmacology platform, Passkey leverages recent advances in computational and genomic methods to develop novel therapeutics. The business model centers on creating drugs that address the intricate interplay of biological pathways influenced by genetics and the environment. By targeting the molecular and cellular mechanisms of disease, Passkey aims to produce treatments with superior efficacy and fewer side effects compared to conventional therapies. The company serves healthcare providers and patients affected by these widespread and inadequately treated conditions. Keywords: drug discovery, metabolic diseases, cancer, Rational Polypharmacology, genomic methods, lipid disorders, obesity, diabetes, tumor biology, novel therapeutics.
Company overview
Passkey Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2023
- Headquarters
- Cambridge, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 56.3
Valuation & funding
Passkey Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Oct 2024 | $20M | $80M | Wireframe Ventures · Innovation Endeavors · Alexandria Venture Investments · GRIDS Capital | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 9 |
| 2025 | 10 |
| 2024 | 17 |
| 2023 | 3 |
Growth signals
Passkey Therapeutics website traffic
Latest recorded traffic for Passkey Therapeutics is 1K monthly website visits, up 63.9% over the last three months. Passkey Therapeutics's team declined 20% over the past year.
Comparisons
Passkey Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Passkey Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Passkey Therapeutics has talent and traffic
team presence
In the news
Latest news about Passkey Therapeutics
Recent press, funding announcements, and product moves mentioning Passkey Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Passkey Therapeutics
An AI-synthesized read of the highest-engagement posts about Passkey Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Passkey Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.